Cargando…
Super-enhancer in prostate cancer: transcriptional disorders and therapeutic targets
Abnormal activity of oncogenic and tumor-suppressor signaling pathways contributes to cancer and cancer risk in humans. Transcriptional dysregulation of these pathways is commonly associated with tumorigenesis and the development of cancer. Genetic and epigenetic alterations may mediate dysregulated...
Autores principales: | Chen, Xuanrong, Ma, Qianwang, Shang, Zhiqun, Niu, Yuanjie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677538/ https://www.ncbi.nlm.nih.gov/pubmed/33299103 http://dx.doi.org/10.1038/s41698-020-00137-0 |
Ejemplares similares
-
A narrative review of proteolytic targeting chimeras (PROTACs): future perspective for prostate cancer therapy
por: Chen, Xuanrong, et al.
Publicado: (2021) -
Increased expression of CELSR3 indicates a poor prognostic factor for Prostate Cancer
por: Chen, Xuanrong, et al.
Publicado: (2021) -
Downregulation of LOX promotes castration-resistant prostate cancer progression via IGFBP3
por: Chen, Xuanrong, et al.
Publicado: (2021) -
Increased KIF4A expression is a potential prognostic factor in prostate cancer
por: Gao, Hongwei, et al.
Publicado: (2018) -
Post-transcriptional modification of m(6)A methylase METTL3 regulates ERK-induced androgen-deprived treatment resistance prostate cancer
por: Li, Yang, et al.
Publicado: (2023)